Cetuximab
BRAF
Zhejiang Universitymonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the BRAF cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fruquintinib Zhejiang University | Phase 2 | CCC |
s241656 Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
Irinotecan Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
FLUOROURACILUM Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
Calcium folinate pentahydrate Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
PANITUMUMAB Institut de Recherches Internationales Servier | Phase 1/2 | CCC |
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →